NewAmsterdam Pharma (NAMS) Change in Account Payables (2023 - 2026)
NewAmsterdam Pharma (NAMS) reported Change in Account Payables of -$793000.0 for Q1 2026, down 135.23% on a YoY basis from $2.3 million in Q1 2025, and down 114.91% sequentially from $5.3 million in Q4 2025.
NewAmsterdam Pharma (NAMS) Change in Account Payables (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 4 years of Change in Account Payables data on file, last reported at -$793000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 135.23% year-over-year to -$793000.0; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 178.16% YoY), and the FY2025 full-year result was $4.9 million, up 137.91% from the prior year.
- Change in Account Payables slipped to -$793000.0 in Q1 2026, from $5.3 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $12.9 million in Q4 2023 to a low of -$9.2 million in Q3 2023.
- A 4-year average of -$289384.6 and a median of -$793000.0 in 2026 frame the typical range for Change in Account Payables.
- Peak annual rise in Change in Account Payables reached 266.34% in 2025, while the deepest fall reached 219.11% in 2025.
- Tracing NAMS's Change in Account Payables over 4 years: stood at $12.9 million in 2023, then plunged by 124.79% to -$3.2 million in 2024, then jumped by 266.34% to $5.3 million in 2025, then sank by 114.91% to -$793000.0 in 2026.
- Business Quant data shows NAMS's Change in Account Payables at -$793000.0 in Q1 2026, $5.3 million in Q4 2025, and -$2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | NewAmsterdam Pharma | 3.72 Bn | 3.72 Bn | - | -793,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -793,000.00 |
| Mar 31, 2026 | -793,000.00 |
| Dec 31, 2025 | 5.32 Mn |
| Dec 31, 2025 | 5.32 Mn |
| Sep 30, 2025 | -2.27 Mn |
| Sep 30, 2025 | -2.27 Mn |
| Jun 30, 2025 | -391,000.00 |
| Jun 30, 2025 | -391,000.00 |
| Mar 31, 2025 | 2.25 Mn |
| Mar 31, 2025 | 2.25 Mn |
| Dec 31, 2024 | -3.20 Mn |
| Dec 31, 2024 | -3.20 Mn |
| Sep 30, 2024 | 1.91 Mn |
| Sep 30, 2024 | 1.91 Mn |
| Jun 30, 2024 | -3.35 Mn |
| Jun 30, 2024 | -3.35 Mn |
| Mar 31, 2024 | -8.31 Mn |
| Mar 31, 2024 | -8.31 Mn |
| Dec 31, 2023 | 12.89 Mn |
| Dec 31, 2023 | 12.89 Mn |